Half-Year 2022 Financial and Clinical Trials Update
HY 2022: Diagnostics Division sales
Sales increase of +11% driven by COVID-19 testing and base business
2022
2021
Change in %
CHFM
CHFM
CHF
CER
Diagnostics Division
9,948
9,042
10
11
Core Lab
3,875
3,770
3
4
Point of Care 1
2,609
1,798
45
46
Molecular Lab¹
1,980
1,990
-1
1
Diabetes Care
832
894
-7
-5
Pathology Lab
652
590
11
10
Roche
CER-Constant Exchange Rates; underlying growth of Core Lab excluding Roche Information Solutions: +4%; 1 Sales in the Point of Care customer area include sales from the Liat business (POC molecular), and sales in the
Core Lab customer area include sales from the Life Science Alliances, both previously shown as part of Molecular Lab customer area. The comparative information for 2021 has been updated accordingly. In Q1 21 POC
molecular sales=90mCHF, Q2 21=92mCHF, Q3 21=175mCHF, Q4 21=194mCHF. In Q1 21 LS Alliances-21mCHF, Q2 21-23mCHF, Q3 21-23mCHF, Q4 21=20mCHF.
59
35View entire presentation